MBX Biosciences, Inc. Common Stock

NASDAQ:MBX

Biotechnology

Healthcare
$53.42 -1.54%

-$0.64 today

Market cap
$2.65B
Beta
0.75
P/E (TTM)
-22.0
EPS (TTM)
-$1.86
52W Low $9.43High $45.85

Volume 0.73M

Average 0.65M

MBX Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

MBX Biosciences, Inc. Common StockNASDAQ: MBX

Financing Cash Flow · Q3 FY2026 · quarter ended Sep 2026

Financing cash flow dips below year-ago levels

Q3 FY2026 financing cash flow of $99.61M fell 47.0% year over year, behind the +0.4% change in trailing-twelve-month financing cash flow. Sequentially, it rose 4191.8% from the prior quarter. Over 3 fiscal years it compounded at +60.3% a year.

Context

  • Financing cash flow increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -47.0% toward the trailing-twelve-month pace of +0.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$99.61M+4191.8% QoQ
Last fiscal yearDec 2025
$189.59M-19.0% YoY
LTMSep 2026
$189.81M+0.4% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-47.0%——
1 year-19.0%——
3-year CAGR+60.3%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
189.59M USD
Year-over-year change
-19.0%
3-year CAGR
+60.3%

Financing Cash Flow vs competitors

How MBX compares with its peers on the latest reported figures

  • Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +0.4% is the 5th highest of 8, against a peer median of +363.0%.
  • Over three fiscal years its annual growth of +60.3% compares with a peer median of +27.3%.
MBX Competitors
Financing Cash Flow for MBX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
KLRAKailera Therapeutics, Inc.FY2025$598.66M USD———
ALTAltimmune, Inc.LTM Mar 2026$251.49M USD+466.1%+53.9%698594.4%
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026$189.81M USD+0.4%+60.3%—
ASNDAscendis Pharma A/SLTM Sep 2026€113.07M EUR-505.3%-55.5%9.4%
VKTXViking Therapeutics, Inc.LTM Jun 2026$111.25M USD+2441.0%+163.8%—
BMEABiomea Fusion, Inc.LTM Mar 2026$64.53M USD+1243.2%+279.8%—
RYTMRhythm Pharmaceuticals, Inc.LTM Sep 2026$15.76M USD-106.1%+0.6%5.6%
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$15.14M USD-54.2%——
XERSXeris Biopharma Holdings, Inc.LTM Mar 2026$5.69M USD+363.0%-55.3%1.8%
Peer median (excluding MBX) —+363.0%+27.3%7.5%

Competitors are the stored peer set for MBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(26.14M)(32.56M)(61.92M)(86.97M)
Depreciation & Amortization56K157K244K248K
Deferred Income Tax0000
Stock-Based Compensation306K2.04M5.22M8.68M
Change in Working Capital1.29M(735K)4.6M1.58M
Accounts Receivables0000
Inventory0000
Accounts Payables671K412K3.93M(2.46M)
Other Working Capital619K(1.15M)670K4.03M
Other Non-Cash Items1.36M(880K)(2.82M)(3.48M)
Operating Cash Flow(23.12M)(31.98M)(54.68M)(79.95M)
Capital Expenditures(441K)(129K)(874K)(1.93M)
Acquisitions (Net)0000
Purchases of Investments(20.22M)(63.8M)(239.47M)(358.15M)
Sales of Investments9.25M33M79.75M267.87M
Other Investing Activities0008.5M
Investing Cash Flow(11.41M)(30.93M)(160.6M)(83.71M)
Debt Repayment10M000
Common Stock Issued30K739K174.54M189.59M
Common Stock Repurchased0000
Dividends Paid0000
Other Financing Activities(428K)(30K)(3.94M)0
Financing Cash Flow46.06M69.22M234.1M189.59M
Effect of Forex Changes0000
Net Change in Cash11.53M6.31M18.83M25.94M
Free Cash Flow(23.56M)(32.11M)(55.56M)(81.88M)

MBX Biosciences, Inc. Common Stock

NASDAQ:MBX

Intrinsic Alpha fair value

Locked

Current Price

$53.42

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.